Jonathan Riess MD, Hematology/Oncology Fellow (PI: Heather Wakelee)
Stem Cell Pathways in Thymoma
Thymic malignancies are rare and there is a paucity of data on the biology as well as therapeutics. The goal of this project is to explore thymic malignancies for the presence and activity of novel stem cell signaling pathways to provide a pre-clinical rationale for further study of potential therapeutic targets.
Jamie Haddon, PhD, Postdoctoral Fellow in the Division of Immunology & Rheumatology (PI: PJ Utz)
Proteonomics of Systemic Sclerosis and Response to Abatacept Systemic sclerosis (SSc) is a chronic disease that causes widespread fibrosis of the skin, lung and kidney, resulting in substantial mortality. We aim to identify new diagnostic and prognostic biomarkers for SSc and identify the inflammatory mechanisms for this disease. The results from this proposal will provide insights into the diagnosis, pathogenesis, and treatment of SSc.
Huong (Marie) T. Nguyen, MD, Hematology/Oncology Fellow (PI: Jason Gotlib)
Interrogating Changes in the Phosphatidylinositol 3-Kinase (PI3K)/AKT Signaling Pathway in Myelofibrosis Patients Treated with the PI3 Kinase Inhibitor CAL-101 Using Phospho-Flow Cytometry and Nanofluidic Proteomic Immunoassay
Myelofibrosis (MF) is a hematologic malignancy with a median survival of only 2-4 years in intermediate to high risk patients. We aim to develop assays to characterize PI3K/AKT signaling and its inhibition in MF patients. Ultimately, we aim to correlate changes in PI3 kinase-signaling with patient clinical outcomes.
Everett Meyer MD, PhD, Clinical Fellow in Bone Marrow Transplantation (PI: Robert Negrin)
T Cell Immune Repertoire Studies in Graft-Versus-Host-Disease A key to the success of hematopoietic stem cell transplantation in curing diseases is due to donor T cells, but these T cells can attack recipients and cause graft versus host disease. We propose to use new technologies to identify and functionally profile T cell clones implicated in graft versus host disease.
Catherine Blish, MD, PhD (Principal Investigator), Assistant Professor of Medicine (Infectious Diseases)
David Katzenstein, MD, Professor of Medicine (Infectious Diseases)
Andrew Zolopa, MD, Associate Professor of Medicine (Infectious Diseases)
Residual HIV viral diversity and its relationship to the chronic inflammation of well treated HIV-infected adults. This project seeks to improve our understanding of why the immune system does not fully recover from HIV infection despite effective antiretroviral therapy. Since chronic inflammation is thought to contribute to morbidity and mortality from cardiovascular and other diseases, better understanding of how the virus contributes to this inflammation will drive the development of new therapeutics and may shape the antiretroviral use for optimal outcomes.
Jonathan Benjamin, MD, PhD, Assistant Professor of Medicine (Blood & Marrow Transplantation)
David Miklos, MD, PhD, Assistant Professor of Medicine (Blood & Marrow Transplantation)
Development of immunoglobulin high-throughput sequencing for Multiple Myeloma minimal residual disease quantification. Using high-throughput sequencing of the clonally rearranged immunoglobulin gene (IGH-HTS), we seek to obtain a more precise measurement of Multiple Myeloma disease burden in patients undergoing autologous stem cell transplantation (ASCT). This technology will help us determine whether disease relapse is due to insufficient tumor eradication with high dose therapy or because of graft contamination.
Michaela Liedtke, MD, Assistant Professor (Hematology)
Isabella Graef, MD, PhD, Assistant Professor (Pathology)
Therapeutic strategies for transthyretin-induced cardiac amyloidosis Transthyretin (TTR) - related amyloid cardiomyopathy affects 4% of African Americans and 10-15% of adults over the age of 65, causing restrictive cardiomyopathy, arrhythmias, and death, but no approved therapies exist for this life-threatening disease. The long-term objective of our project is the development of potent and selective TTR stabilizing compounds as therapeutics for amyloid cardiomyopathy.
Lauren Harshman MD (Principal Investigator), Assistant Professor (Oncology)
James D. Brooks MD, Associate Professor (Urology)
Alice C. Fan MD, Instructor of Medicine (Oncology)
John T. Leppert MD, Assistant Professor of Medicine (Urology)
Sabatti, Chiara PhD, Associate Professor (Biostatistics)
Sandy Srinivas, MD, Associate Professor (Oncology)
Development of Blood Biomarkers for Diagnosis and Monitoring of Renal Cell Carcinoma We aim to develop new proteomic biomarkers for diagnosis and monitoring therapeutic response in kidney cancer using a novel nanoscale immuno-assay to profile blood and a new capture assay to isolate circulating tumor cells from patients. The data from this proposal will be used to design new correlative tests for use in the first time in clinical trials of solid tumors at Stanford.